Skip to main content

Table 3 Multivariate prognostic factor analysis for PFS and OS

From: Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data

  HR (95 % CI) p-value
Progression-free survival
ECOG PS, 1/2 vs. 0 1.94 (1.31-2.89) 0.001
CA19.9, ≥157 U/ml vs. <157 U/ml 1.58 (1.08-2.33) 0.019
Gender, female vs. male 1.49 (1.04-2.14) 0.028
Lung metastases, yes vs. no 1.48 (1.02-2.14) 0.040
Overall survival
ECOG PS, 1/2 vs. 0 3.56 (2.25-5.61) <0.001
Stage, metastatic vs. locally advanced 3.25 (1.58-6.69) 0.001
CA19.9, ≥157 U/ml vs. <157 U/ml 1.96 (1.25-3.05) 0.003
  1. Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, HR hazard ratio; 95 % CI, 95 % confidence interval